No Help from Continuous Tx in Metastatic RCC, Memorial Sloan-Kettering Cancer Center Study

MedPageToday -- ORLANDO -- Outcomes in metastatic renal cell carcinoma did not improve with continuous dosing of sunitinib (Sutent) compared with the conventional 4/2 dosing regimen, results of a multicenter randomized trial showed. Response rates, survival, and adverse-event profiles were similar between patients who received 37.5 mg/d continuously and those treated with 50 mg/d for four weeks followed by a two-week break, according to Robert Motzer, MD, of Memorial Sloan-Kettering Cancer Center in New York.